The unpredictable intestinal absorption and erratic bioavailability of oral busulfan (Bu) has limited the drug's use in high-dose pretransplantation conditioning therapy. To standardize drug delivery, we solubilized Bu for parenteral use. This new intravenous (IV) Bu formulation was combined with oral Bu and cyclophosphamide (Cy) to evaluate (1) the human acute toxicity of IV Bu and its solvent system and (2) the pharmacokinetics of Bu in patients undergoing hematopoietic progenitor cell transplantation (HPCT). One dose of IV Bu (escalating from 0.08 to 0.8 mg/kg) was given over 2 hours by pump; 6 hours later, an oral Bu regimen was begun, consisting of 1 mg/kg every 6 hours for 15 doses, followed by Cy, 60 mg/kg daily for 2 days. After 1 day of rest, HPCT was performed. The IV Bu dose was well tolerated and did not produce any acute toxicity reaction that could be attributed to the solvent system of dimethylacetamide and polyethylene glycol (PEG)-400. All observed treatment-related toxicity was as would be expected after high-dose oral Bu plus Cy. When the IV Bu was used as reference solution, the pharmacokinetic analysis indicated an average bioavailability of oral high-dose Bu of 69%, ranging from <10% to virtually 100%. Further, the 2-hour infusion of IV Bu gave a time to maximum plasma concentration following drug administration similar to that of oral Bu (2 hours and 1.8 hours, respectively), and IV Bu had a clearance similar to that of oral Bu. Based on the data in this study, we suggest that the optimal (starting) dose of IV Bu (in combination with Cy) in our forthcoming phase 2 trial should be on the order of 0.8 mg/kg to target an area under the curve (AUC) of 1100 to 1200 µmol/L per minute. This would secure myeloablation and engraftment but save the vast majority of patients from the increased risk of serious hepatic veno-occlusive disease that has been reported when the AUC level exceeds 1500 µmol/L per minute. Bu administration via the IV route will assure complete bioavailability and reliable systemic drug exposure with more predictable blood levels and, therefore, possibly lower the risks for serious/lifethreatening toxicity, graft rejection, and recurrent leukemia.
INTRODUCTION
High-dose oral busulfan (Bu) in combination with cyclophosphamide (BuCy) or other cytotoxic agents is widely used in pretransplantation conditioning therapy before hematopoietic progenitor cell transplantation (HPCT).
B B & M T
Bu-based combinations are important alternatives to total body radiation-based therapy, and numerous clinical trials demonstrate their efficacy [1] [2] [3] [4] [5] . Because of variable absorption of Bu in the gastrointestinal tract, there is unfortunately marked interindividual variation in oral Bu pharmacology, variations that may reach 10-fold or larger [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Interdose variations in Bu bioavailability can also be significant. Further, vomiting after oral dosing frequently occurs, and factors such as gastric pH may also affect intestinal drug absorption [10, [13] [14] [15] .
The unpredictable pharmacology of Bu is important: several investigators have reported that high Bu blood concentration-versus-time area under the curve (AUC) correlates with serious side effects in the liver [6, [16] [17] [18] and central nervous system (CNS) [15, 19] , whereas low blood Bu AUC levels have been connected with an increased risk for graft rejection and recurrent leukemia after transplantation [20, 21] . To circumvent both the erratic, unpredictable intestinal Bu absorption and the hepatic first-pass effect that might contribute to hepatic veno-occlusive disease (VOD) [22] , we developed a pharmaceutically acceptable parenteral Bu formulation [23, 24] . After testing the safety of this formulation in a large-animal model [25] , the current human modified phase 1 trial was conducted. The objectives of this study were (1) to determine whether Bu in the solvent system consisting of dimethylacetamide (DMA) and polyethylene glycol (PEG)-400 (1:2, vol/vol) could be safely administered in humans without acute toxicity from the solvent vehicle and (2) to determine the IV Bu dose that would achieve an AUC similar to that of oral Bu when the latter was given at a dose of 1.0 mg/kg. This IV dose would be used in our forthcoming phase 2 studies, in which all Bu doses would be administered via the parenteral route.
PATIENTS AND METHODS

Patients
Patients with the following hematologic malignancies were eligible for this study, provided that they did not qualify for an institutional treatment protocol of higher priority: (1) acute leukemia past first remission or refractory to induction chemotherapy, (2) chronic myeloid leukemia past first chronic phase, or (3) primary refractory or resistant relapsed Hodgkin's disease or non-Hodgkin's lymphoma. The eligibility criteria also included ages between 16 and 55 years (physiological age); normal renal and hepatic function (creatinine ≤1.5 mg/100 mL, bilirubin ≤1.0 mg/100 mL, alanine transaminase <3ϫ upper normal level); a cardiac left ventricular ejection fraction of ≥50%; pulmonary function tests, including forced expiratory volume in 1 second (FEV 1 ) and carbon monoxide diffusion capacity (DLCO) ≥50% of predicted; negative serology for hepatitis and HIV infection; and a life expectancy of at least 12 weeks. Patients were eligible for this study if either autologous or allogeneic progenitor cells from an HLA-matched related donor were available. In accordance with institutional guidelines, all patients gave written informed consent before study entry.
Treatment Plan
The treatment was modified from Tutschka et al. [26] : Bu was administered every 6 hours for a total of 16 doses (days -7 to -4) followed by cyclophosphamide 60 mg/kg IV over 1 hour on 2 consecutive days (days -3 and -2). The first (IV) Bu dose (Busulfex Injection; Orphan Medical, Minnetonka, MN) was diluted in normal saline or 5% dextrose in water (D5W) to 0.5 mg/mL and infused over 2 hours by pump through a central venous catheter. The Busulfex solution diluted in either normal saline or D5W is stable for at least 8 hours at room temperature; when diluted in normal saline, it is stable for 12 hours if refrigerated [27] . An infusion time of 2 hours was chosen to mimic the literaturereported values, where the time of maximum plasma concentration following drug administration (T max ) of Bu after oral administration was reported to be on the order of 1 to 2 hours. The starting dose was 0.08 mg/kg body weight (the lower of actual or ideal weight), based on the preclinical safety data from the large-animal (beagle) model [25] . The IV Bu dose was escalated to 0.2 mg/kg, then to 0.4 mg/kg, and finally to 0.8 mg/kg in cohorts of 3 patients at each dose level. At the final level, 3 additional patients were treated to confirm the pharmacokinetic (PK) findings. Six hours after the start of the IV Bu infusion, the patients began to receive oral Bu at 1.0 mg/kg every 6 hours for 15 doses. Bone marrow or granulocyte colony-stimulating factor (G-CSF)-stimulated blood progenitor cells were infused after a day of rest. Prophylaxis against graft-versus-host disease was done using cyclosporine A and low-dose methotrexate. Engraftment was assessed by peripheral blood counts and marrow examination. Adverse events were evaluated using the modified National Cancer Institute (NCI) criteria.
Pharmacokinetics
Blood samples (5 mL) for PK analysis were collected in heparinized tubes immediately before the administration of IV Bu; at 15, 30, 45, and 115 minutes after the start of the 2-hour infusion; and at 15, 30, 60, 120, 180, and 240 minutes after the end of infusion. In addition, blood samples were drawn immediately before and at 15, 30, 45, 60, 75, 90, 120, 240 , and 360 minutes after administration of the fifth (fourth oral) Bu dose.
Samples were analyzed as previously described [28] [29] [30] . Briefly, the blood samples were transported on ice to the laboratory. Plasma was separated by centrifugation at 2500 rpm for 10 minutes at 4°C within 1 hour, placed in cryogenic vials, and stored at -40°C until analysis. All plasma samples from each patient were thawed just before analysis and deproteinated with acetonitrile, and the supernatant was derivatized with 5% (wt/vol) diethyldithiocarbamate and 25 mmol/L ammonium acetate to 1,4-bis(diethyldithiocarbamoyl) butane. The derivatized Bu was extracted using a 3-step liquid-liquid extraction procedure with ethyl acetate, and the resulting supernatant was slowly dried at 45°C under a gentle nitrogen flow. The samples were reconstituted with 100 µL methanol, and 50 µL was injected onto the high-performance liquid chromatography (HPLC) system for analysis, using a Waters model 717-Plus Autosampler (Waters, Milford, MA). Separation was achieved by isocratic elution using a mobile phase of methanol (80% vol/vol) in water, at a flow rate of 1.0 mL/min (model 616 Pump + 600S Controller; Waters). Busulfan was isolated using a C18 analytical column and pre-column guard filter (Nova-Pak C18, 250 ϫ 4.6 mm, 4 µm particle size). The analytical column was maintained at an ambient temperature of 30°C. The column effluent was monitored using a photodiode array detector over wavelengths from 220 to 320 nm. A derived channel of 254 nm was extracted to create chromatograms for peak analysis. The Bu peak was identified using ultraviolet (UV) absorbance spectral analysis and retention time (Bu = 7.5 min), with Bu concentrations determined by a calibration curve using external standardization.
No co-eluting peaks were observed in either standards or patient samples. The interday and intraday coefficients of variation were less than 15%, with a lower limit of quantification of 50 ng/mL, and the detector response was linear for extracted plasma samples containing up to 10 µg/mL of Bu. Various compartmental models were fit to each sample's Bu concentration-time data, using maximum likelihood estimation and data weighed as 1/y 2 . Model selection was determined using Akiake's information criteria [31] , visual inspection, and statistical estimation of fit. The best fit of the plasma-concentration-time data was observed with an open 2-compartment model for the IV drug data, whereas a 1-compartment model was adequate for the oral drug data. Parameters such as volume of distribution of the central compartment, elimination rate constant, and microconstants were estimated, whereas steady-state volume of distribution, t 1/2 , and clearance were calculated from the primary parameters. After IV dosing, the recorded half-life was based on the open 2-compartment model, and after oral dosing the terminal half-life was recorded. The plasma concentration versus time AUC was calculated from the model-derived parameters. The PK modeling was performed using ADAPT II Software Version 4.0 (BMRS, University of Southern California, Los Angeles, CA) [32] .
RESULTS
The 15 patients treated on this protocol had advanced hematologic malignancies: 10 patients had recurrent nonHodgkin's lymphoma, 3 had Hodgkin's disease, and 2 had recurrent acute myeloid leukemia. There were 11 men and 4 women with a median age of 46 years (range, 19-58 years). Two patients received allogeneic peripheral blood progenitor cells (PBPCs) from tissue-compatible sibling donors. The remaining (autologous) patients received PBPC (11 patients), bone marrow (1 patient), or a combination of bone marrow and PBPC (1 patient).
Aside from minimal nausea, no acute side effects could be attributed to the Bu or solvent system during the infusion of the first drug dose. The side-effect spectrum experienced with the regimen paralleled what had been previously described in patients preconditioned for HPCT with the BuCy2 regimen when all 16 Bu doses were administered orally [1] [2] [3] [4] [5] 26 ]-ie, nausea, mild mucositis, and (in 2 cases) mild to moderately severe hepatic VOD, which resolved with conservative management in both patients. No patient experienced neurologic toxicity. Engraftment (defined as 0.5 ϫ 10 9 neutrophils/L) was recorded at a median of 12 days (range, 10 to 25 days) for the 13 patients who had an autologous HPCT and at 8 and 15 days for the 2 patients who received an allogeneic graft.
PK Analysis
Complete PK data, including data from both the IV and the oral dose administrations, were available from only 10 of the 15 patients treated in the study (Tables 1 and 2 ). One patient vomited shortly after the fifth (fourth oral) Bu dose. He received a second oral dose to replace what was believed to have been lost in the vomitus, but was considered inevaluable for calculating the oral dose PK parameters because it was impossible to determine the total amount of oral Bu that he had received. This patient was analyzed only for acute toxicity/clinical tolerance of the IV Bu dose and for calculating the PK parameters after the IV dose. In addition, the data from 4 patients were lost due to instrument malfunction, as insufficient sample volume remained to allow a repeat analysis. 
B B & M T
A complete PK profile was obtained from 5 of 6 patients at the highest IV Bu dose level (0.8 mg/kg). The median t 1/2 was 3.8 hours (range, 0.6-6.5 hours) with IV Bu compared with 1.8 hours (range, 0.6-2.3 hours) after oral drug. Total Bu plasma clearance after IV Bu was 2.6 mL/min per kg (range, 0.94-3.54 mL/min per kg), similar to the apparent clearance after oral administration (3.4 mL/min per kg; range, 2.1-8.1 mL/min per kg). The IV Bu consistently yielded plasma AUC profiles (mean 1189 µmol/L per min; range, 964-1547 µmol/L per min) similar to those observed after oral drug (mean of 1135 µmol/L per min; range, 461-1933 µmol/L per min), but with much less interpatient variation (Tables 1 and 2 ). The bioavailability of oral Bu was highly variable among individuals (Table 2 ), in spite of our attempts to standardize the delivery of oral drug (fasting, consistent schedule, attempted control of nausea/vomiting). Even though the bioavailability after oral dosing averaged 69%, the coefficient of variation was >40%, and 2 of the 10 evaluable patients absorbed <15% of the given dose.
An example of the predictable plasma concentration versus time curve obtained using the IV formulation is demonstrated in the Figure. The oral data from the same patient (number 10) demonstrated the often unpredictable delay in absorption and a varied and discontinuous absorption, which resulted in a biphasic plasma concentration pattern during this dosing interval.
DISCUSSION
The wide variability in both interpatient and intrapatient Bu bioavailability after oral administration has hampered the effectiveness of Bu-based high-dose pretransplantation conditioning therapy. Slattery and colleagues [20, 21] reported that a suboptimal Bu exposure dose after oral BuCy2 increased the risk for both graft rejection and recurrent leukemia after allogeneic HPCT. Further, a high-exposure dose correlated with an increased risk for serious side effects in the CNS and with an increased incidence of hepatic VOD [6, [16] [17] [18] [19] . Finally, both Vassal et al. [13] and Hassan and colleagues [14, 15] demonstrated that the generally overlooked interdose variations in bioavailability after oral dosing may be significant and may contribute to the substantial variability observed in toxicity and response, even when the dose is adjusted based on PK measurements after the earliest doses. An IV formulation would avoid such complications associated with oral drug administration, and in fact, this dosage form minimized the observed interpatient variability characteristics of the oral preparation to those that are the consequences of individual differences in metabolic drug handling. This result is reflected by the 19% coefficient of variation of AUC after IV dosing versus 37% after oral dosing. When we used the IV Bu formulation as the reference point for PK calculations, the bioavailability of oral drug in the present study was estimated to average 69%, confirming the previous estimates in the range of 60% to 80% made after delivery of low doses of IV and oral Bu [14] and after administration of higher-dose oral and IV Bu in pretransplantation therapy using a dimethyl sulfoxide (DMSO)-based formulation [33] . Although the average bioavailability of oral Bu in the current study was 69%, the range was surprisingly high, varying more than 10-fold from the lowest (F < 10%) to the highest (F = 100%) subject, with 2 of the 10 evaluable patients having <15% bioavailability of oral drug. The fact that 1 patient was pharmacokinetically inevaluable due to drug loss through vomiting highlights a major problem associated with the oral formulation. Together with the erratic absorption inherent in the oral preparation, loss of drug through emesis becomes the single largest impediment to PK-guided dose individualization of high-dose Bu.
In the current study, we found no acute side effects that could be attributed to the solvent system. Thus, the new IV Bu formulation is appropriate for administration in continued human clinical trials. The decision to use a cosolvent system of DMA and PEG-400 was based on several considerations; *Percentage bioavailability was calculated as (AUC oral /AUC IV ) ϫ 100 and the AUC IV was normalized to a dose of 1 mg/kg. Bu indicates busulfan; Vc, central volume; Cl, apparent total clearance normalized to actual body weight; AUC, calculated area under the concentration-time curve.
†Busulfan was detectable but below the limits of quantification for this oral dose.
there is extensive experience with the pharmaceutical use of both DMA and PEG-400 as the basis for a composite solvent system for anticancer agents. For example, both the investigational agent m-AMSA and (the commercially available) teniposide (Vumon) use DMA-based formulations [34, 35] , and (the commercially available) L-asparaginase [36] and ␣-interferon [37] pharmaceutical formulations use PEG or PEG-400 [38] as a cosolvent or a covalent-bound carrier. Additionally, DMA is an excellent solvent for Bu [23, 24] . Further, DMA is in itself a potent inducer of myeloid cell differentiation; in this aspect, it is at least 25-fold more potent than DMSO [39] . Finally, DMA has in itself shown activity as an anticancer agent when it was tested in an NCIsponsored phase 1 trial [40] . In the NCI trial, the dose-limiting toxicities of DMA were reported as mild, transient impairment of liver function and reversible confusion and stupor; in a few patients, delayed visual and auditory hallucinations appeared at doses exceeding 400 mg/kg daily for 5 days. The maximum total DMA dose of the present Bu formulation if used in an IV Bu-based myeloablative regimen (BuCy2) in an adult patient can be calculated to be about 40% of that reported as necessary to result in adverse effects when DMA was administered as a single agent [41] . By comparison, when teniposide was used in dose-intensive chemotherapy, the delivered DMA dose approached or often exceeded the dose that would be achieved if the current (Busulfex) formulation were used in a myeloablative regimen (deduced from [41] [42] [43] ). The most serious adverse events reported after doseintensive therapy with teniposide have been myelosuppression and mucositis. Only 1 report described CNS events such as somnolence, hypotension, and stupor, in 3 pediatric patients who received teniposide as a 4-hour infusion at a dose of >600 mg/m 2 [44] . These authors concluded, however, that the most likely reason for CNS depression in their patients was the high ethanol content in the teniposide formulation [44] , which in combination with a high infusion rate yielded high, toxic ethanol concentrations in the CNS [44, 45] . When teniposide was administered as a prolonged, continuous infusion over 72 hours in dose-intensive regimens (>750 mg/m 2 , repeated every 4-5 weeks), no serious adverse CNS events were encountered [46] . As for the uses of PEG-400 in the formulation, this was used as a cosolvent to stabilize the Bu in solution and make it possible to dilute it with normal saline or D5W without precipitation of Bu in the infusate. Based on the literature, no serious adverse effects should be expected in the dose range of PEG-400 achieved in an IV Bu-based conditioning program.
Based on the PK parameters obtained for Bu after oral versus IV administration in this study, we think that an appropriate starting dose of IV Bu for our forthcoming phase 2 study would be 0.8 mg/kg per dose, given the observed median IV Bu plasma clearance of approximately 2.6 mL/min per kg and the mean AUC of 1189 µmol/L per minute as listed in Table 1 . This assumes that if we retain the BuCy2 schedule of the present study, the repetitive 0.8 mg/kg dose should result in a mean AUC in the study population of approximately 1100-1200 µmol/L per minute, well below the AUC of 1500 µmol/L per minute that has previously been associated with an increased risk for VOD [18] . This target AUC should be sufficient to assure engraftment and secure a pronounced antileukemic effect, yet reduce the risk for serious VOD and CNS toxicity. It should be recognized, however, that the suggested IV Bu dose of 0.8 mg/kg as appropriate for a phase 2 trial is based on a limited amount of PK information, because there was no alternative commercially available IV product available for comparative PK studies, and very limited information exists about the metabolic disposition of IV-administered Bu. However, our reported median plasma clearance after Plasma busulfan concentration (Conc) versus time plots for busulfan after administration of intravenous (IV) drug and oral drug, respectively, from patient number 10. Derived pharmacokinetic parameters were used to simulate the oral data, such that comparable plasma concentration-time curves could be represented under non-steady-state conditions after both IV and oral dosing. Data were normalized to a dose of 1.0 mg/kg.
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B B & M T
IV Bu is similar to that reported by Hassan et al. [14] in a limited trial of low-dose IV Bu in a complex formulation system in adults (2.6 versus 2.49 mL/min per kg) and that of Schuler et al. [33] using a DMSO-Bu formulation. Thus, our preferred dose of 0.8 mg/kg in the modified BuCy2 regimen should be considered only a starting dose for a phase 2 study; the definitive IV Bu dose for myeloablative regimens may later be modified to account for any changes in the side-effect profile when the total Bu dose is administered parenterally. The optimal infusion time and administration schedule have yet to be determined for IV Bu, but the 2-hour infusion resulted in a T max that was similar to that observed after the oral drug (2.0 hours for IV versus 1.8 hours for the oral formulation). Additionally, the similarity of the mean t 1/2 and clearance measurements after IV Bu in this study to those reported in several previous studies of oral Bu suggest that the solvent system did not influence Bu metabolism. However, it should be confirmed that repeated IV doses do not significantly alter the Bu PK profile compared with the oral Bu preparation.
Further clinical studies using this IV Bu formulation are warranted. The parenteral route of Bu administration will assure complete bioavailability with more predictable blood levels via controlled infusion and lessen the risks for serious/life-threatening toxicity as well as (possibly) lowering the risks for graft rejection and recurrent leukemia after transplantation.
